COVID-19

Outside of the loss of human life due to the COVID-19 pandemic, the past two years have greatly affected hospitals, health systems and the way providers deliver care. Healthcare executives are grappling with federal monetary assistance, growing burnout rates, workforce shortages and federal oversight of vaccines and testing. This channel is also designed to update clinicians on new research and guidelines regarding COVID patient treatment strategies and risk assessments.

RSS icon
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
Thumbnail

American Heart Association dedicates another $2M to COVID-19 research

“We were just blown away and so impressed to see this level of interest and commitment from the teams submitting such thorough proposals so quickly,” said AHA President Robert A. Harrington, MD.

Thumbnail

Novartis launches FDA-approved study involving hydroxychloroquine, azithromycin, COVID-19 patients

Novartis is launching a new clinical trial to assess the effectiveness of treating hospitalized COVID-19 patients with hydroxychloroquine.

Thumbnail

What high COVID-19 mortality among black patients tells us about CVD care in the US

The high mortality rates from COVID-19 among black patients and other racial/ethnic minorities put a much-needed spotlight on the “deep-rooted failures” of the U.S. healthcare system to improve care for cardiovascular disease (CVD), according to a new commentary.

Thumbnail

First COVID-19 death in US caused by a ruptured heart

The first known death from COVID-19 in the United States was caused by a ventricular rupture.  

Thumbnail

New research highlights the connection between venous thromboembolism and COVID-19

Hospitalized COVID-19 patients experience a high rate of thromboembolic complications, according to new findings published in Thrombosis Research.

Thumbnail

Treating COVID-19 with hydroxychloroquine, with or without azithromycin, leads to more deaths

In addition to these latest findings, a NIH-backed panel is now specifically recommending against the combination of hydroxychloroquine and azithromycin for treating COVID-19 patients.

Thumbnail

CMS allowing some providers to restart in-person care unrelated to COVID-19

CMS has announced that healthcare providers in communities experiencing low numbers of confirmed COVID-19 cases may be able to once again provide more in-person care unrelated to the virus.

Thumbnail

Heart attack care during a pandemic: Medical societies share COVID-19 recommendations

The COVID-19 pandemic has changed patient care in countless ways, but percutaneous coronary intervention (PCI) remains the recommended standard of care for ST-segment elevation myocardial infarction (STEMI) patients.

Displaying 385 - 392 of 430

Around the web

Radiology Business
The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.